Expected Moves

Oct 20, 2026→Oct 30, 2026

Dec 15, 2026→Dec 30, 2026

Year-end progress report on the execution of $800M+ in commercial CDMO orders and synthetic biology project intakes.

Mar 20, 2027→Apr 5, 2027

Full-year 2026 financial disclosure evaluating the inflection point in the company's high-margin CDMO transition.

Jun 15, 2027→Jun 30, 2027

Assessment of evolving US healthcare supply chain legislation and its impact on Chinese CDMO export volumes.